Edwards Lifesciences Corporation $EW Shares Sold by Clarity Capital Partners LLC

Clarity Capital Partners LLC lowered its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 7.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,248 shares of the medical research company’s stock after selling 672 shares during the quarter. Clarity Capital Partners LLC’s holdings in Edwards Lifesciences were worth $645,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of EW. Brighton Jones LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $266,000. Merit Financial Group LLC increased its position in shares of Edwards Lifesciences by 93.4% in the first quarter. Merit Financial Group LLC now owns 10,793 shares of the medical research company’s stock valued at $782,000 after buying an additional 5,212 shares in the last quarter. Unique Wealth LLC purchased a new position in shares of Edwards Lifesciences in the first quarter valued at $248,000. Ehrlich Financial Group increased its position in shares of Edwards Lifesciences by 5.7% in the first quarter. Ehrlich Financial Group now owns 10,950 shares of the medical research company’s stock valued at $794,000 after buying an additional 586 shares in the last quarter. Finally, Radnor Capital Management LLC increased its position in shares of Edwards Lifesciences by 11.1% in the first quarter. Radnor Capital Management LLC now owns 24,070 shares of the medical research company’s stock valued at $1,745,000 after buying an additional 2,400 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Argus upgraded Edwards Lifesciences to a “strong-buy” rating in a research report on Thursday, July 10th. Robert W. Baird raised their price target on Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, July 25th. Stifel Nicolaus set a $85.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a research report on Monday, September 22nd. Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research report on Thursday, August 7th. Finally, BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $86.61.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.5%

Edwards Lifesciences stock opened at $77.03 on Friday. The stock has a 50-day moving average price of $78.50 and a 200 day moving average price of $75.94. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The stock has a market cap of $45.22 billion, a PE ratio of 11.08, a P/E/G ratio of 3.69 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company earned $0.70 EPS. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.